Where Will Galmed Pharmaceuticals Ltd (GLMD) Stock Go Next After It Is Lower By 17.39% in a Week?

Overall market sentiment has been down on Galmed Pharmaceuticals Ltd (GLMD) stock lately. GLMD receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Galmed Pharmaceuticals Ltd has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on GLMD!

See Full GLMD Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With GLMD Stock Today?

Galmed Pharmaceuticals Ltd (GLMD) stock is lower by -9.43% while the S&P 500 has gained 0.68% as of 10:40 AM on Monday, Aug 7. GLMD is lower by -$0.10 from the previous closing price of $1.05 on volume of 66,691 shares. Over the past year the S&P 500 has risen 8.90% while GLMD is lower by -85.95%. GLMD lost -$8.08 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Galmed Pharmaceuticals Ltd click here.

More About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. Click Here to get the full Stock Report for Galmed Pharmaceuticals Ltd stock.